^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Cholesterol absorption inhibitor

    Related drugs:
    7d
    Novel MAFG-METTL14-SCD1 axis regulates lipid metabolism mediating choroidal melanoma distant metastasis. (PubMed, J Exp Clin Cancer Res)
    Our study identifies SCD1-mediated lipid remodeling as a key driver of enhanced membrane fluidity and metastatic potential in CM. Inhibition of SCD1 increases lipid saturation, reduces membrane fluidity, induces oxidative stress, and suppresses liver and lung metastasis. The MAFG-METTL14-SCD1 axis thus represents a critical regulator of CM progression, and combined therapeutic targeting with aramchol and S-HFD offers promising translational potential.
    Journal
    |
    METTL14 (Methyltransferase 14)
    |
    Aramchol (aramchol meglumine)
    10d
    Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Galmed Pharmaceuticals Ltd
    New P1 trial
    |
    Aramchol (aramchol meglumine)
    14d
    The Precision CAD Trial (clinicaltrials.gov)
    P=N/A, N=276, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=450 --> 276
    Enrollment closed • Enrollment change
    18d
    Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Galmed Pharmaceuticals Ltd | Trial completion date: May 2025 --> Dec 2025
    Trial completion date
    |
    Aramchol (aramchol meglumine)
    1m
    Targeting drug-resistant cancers: in silico repurposing of the cholesterol-lowering drug Ezetimibe for selective inhibition of aldo-keto reductase 1B10 (AKR1B10). (PubMed, SAR QSAR Environ Res)
    Quantum mechanical analysis indicated favourable electronic properties and chemical stability. These results suggest that Ezetimibe is a selective and stable AKR1B10 inhibitor, warranting further investigation for drug-resistant cancer therapy.
    Journal
    |
    AKR1B10 (Aldo-Keto Reductase Family 1 Member B10)
    2ms
    Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD. (PubMed, ACS Omega)
    The combination treatment showed a significant reduction of 21.64% (P < 0.05) in lipid accumulation relative to individual treatment with Bixin or Montelukast and was comparable with the reference drug Aramchol (21.83%). The markers of oxidative stress were also significantly reduced (P < 0.05), evidenced by decreased MDA (42.25%), RNS levels (32.59%), and ROS levels (30.72%) in the combination group. These findings suggest that Bixin and Montelukast in combination hold potential for managing the multiple aspects in the pathophysiology of NAFLD development and progression.
    Journal
    |
    SCD (Stearoyl-CoA Desaturase)
    |
    Aramchol (aramchol meglumine)
    2ms
    Musashi: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia (clinicaltrials.gov)
    P=N/A, N=2560, Not yet recruiting, Daiichi Sankyo
    New trial
    3ms
    A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib (clinicaltrials.gov)
    P=N/A, N=8606, Recruiting, Boryung Pharmaceutical Co., Ltd | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    pitavastatin
    3ms
    Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment (clinicaltrials.gov)
    P=N/A, N=18000, Active, not recruiting, Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date • Real-world evidence
    4ms
    GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification (clinicaltrials.gov)
    P4, N=7435, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pitavastatin
    4ms
    Synthesis and lipid-lowering activities of preussin derivatives. (PubMed, Bioorg Med Chem)
    All analogues at 5 μg/mL statistically reduced cholesterol absorption comparable to 40 μg/mL of a positive drug, ezetimibe, without cytotoxic effect to the Caco-2 cells...Remarkably, preussin B significantly modulated hepatic lipid metabolism genes by down-regulating HMGR and up-regulating PPARα, rendering preussin B a new and promising candidate for hypolipidemic and hepatic lipid-lowering agent. Nevertheless, the parent compound, preussin, exhibited the most potent antioxidative effect by markedly scavenging intracellular reactive oxygen species in H2O2-induced oxidative stress condition in both Caco-2 and HepG2 cell lines.
    Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    4ms
    REMBRANDT: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia (clinicaltrials.gov)
    P4, N=146, Completed, Seoul National University Hospital | Recruiting --> Completed | N=240 --> 146
    Trial completion • Enrollment change
    |
    APOB (Apolipoprotein B)